scholarly journals Effect of Non-alcoholic Fatty Liver Disease on the Risk of Synchronous Liver Metastasis: Analysis of 451 Consecutive Patients of Newly Diagnosed Colorectal Cancer

2020 ◽  
Vol 10 ◽  
Author(s):  
Yan Lv ◽  
Hai-jun Zhang
Keyword(s):  
Colorectal Cancer ◽  
Liver Disease ◽  
Liver Metastasis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Newly Diagnosed ◽  
Synchronous Liver Metastasis ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia

2019 ◽  
Vol 6 (1) ◽  
pp. e000307 ◽  
Author(s):  
Igor V Maev ◽  
Aleksey A Samsonov ◽  
Liudmila K Palgova ◽  
Chavdar S Pavlov ◽  
Elena Shirokova ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Alcoholic Fatty Liver ◽  
Number Of Patients ◽  
Metabolic Comorbidities ◽  
Alcoholic Fatty Liver Disease

ObjectivePrevious research conducted in Russia showed that the number of patients with non-alcoholic fatty liver disease (NAFLD) and associated metabolic comorbidities is large. We conducted an observational study to describe the management of NAFLD in patients with metabolic syndrome in Russia.DesignA total of 2843 adult patients from 174 medical sites across 6 federal districts of Russia with newly diagnosed NAFLD, who had at least one of four comorbidities, namely overweight/obesity, hypertension, type 2 diabetes mellitus, and hypercholesterolaemia, and who received phosphatidylcholine (PPC) as an adjunctive treatment to standard care, were enrolled during 2015–2016.ResultsOverall, 2263 patients (79.6%) had at least two metabolic comorbidities associated with NAFLD; overweight/obesity was the most common comorbidity reported in 2298 patients (80.8%). Simple steatosis was the most frequently identified clinical form of NAFLD, diagnosed in 2128 patients (74.9%). Among hypertensive patients, ACE inhibitors, statins, and sartans were most commonly prescribed. Biguanides were administered in more than half of diabetic patients. In patients with overweight/obesity and hypercholesterolaemia, statins were the most frequently prescribed medications. Almost all patients (2837/2843; 99.8%) were treated with 1.8 g of PPC three times per day. PPC therapy was associated with a 90.5% 6-month compliance rate, high treatment satisfaction, and a favourable safety profile. However, almost 15% of diabetic patients and 40% of overweight/obese patients received no further treatment.ConclusionsIn Russia, patients with newly diagnosed NAFLD represent a population heavily burdened by comorbidities, mainly overweight/obesity and hypercholesterolaemia. A significant part of these patients did not receive a comprehensive pharmacotherapy, highlighting the existing unmet need in the current management of NAFLD patients with metabolic syndrome in Russia.

Non-alcoholic fatty liver disease and colorectal cancer

2016 ◽  
Vol 93 (1097) ◽  
pp. 153-158 ◽  
Author(s):  
I Mikolasevic ◽  
L Orlic ◽  
D Stimac ◽  
I Hrstic ◽  
I Jakopcic ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Association between bedtime and the prevalence of newly diagnosed non-alcoholic fatty liver disease in adults

2018 ◽  
Vol 38 (12) ◽  
pp. 2277-2286 ◽  
Author(s):  
Honglei Wang ◽  
Yeqing Gu ◽  
Lixiao Zheng ◽  
Li Liu ◽  
Ge Meng ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Newly Diagnosed ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Non-alcoholic fatty liver disease and colorectal cancer survival

2018 ◽  
Vol 30 (2) ◽  
pp. 165-168 ◽  
Author(s):  
Kana Wu ◽  
Mike Z. Zhai ◽  
Erin K. Weltzien ◽  
Elizabeth M. Cespedes Feliciano ◽  
Jeffrey A. Meyerhardt ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Cancer Survival ◽  
Alcoholic Fatty Liver ◽  
Colorectal Cancer Survival ◽  
Alcoholic Fatty Liver Disease

scholarly journals Association between habitual yogurt consumption and newly diagnosed non-alcoholic fatty liver disease

2019 ◽  
Vol 74 (3) ◽  
pp. 491-499 ◽  
Author(s):  
Shunming Zhang ◽  
Jingzhu Fu ◽  
Qing Zhang ◽  
Li Liu ◽  
Min Lu ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Newly Diagnosed ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study

2019 ◽  
Vol 6 (1) ◽  
pp. e000295 ◽  
Author(s):  
Masahide Hamaguchi ◽  
Yoshitaka Hashimoto ◽  
Akihiro Obora ◽  
Takao Kojima ◽  
Michiaki Fukui
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Cox Proportional Hazards Model ◽  
Alcoholic Fatty Liver ◽  
Incident Rate ◽  
Alcoholic Fatty Liver Disease

BackgroundColorectal cancer is known to be an extrahepatic complication of non-alcoholic fatty liver disease (NAFLD). However, the interaction of NAFLD with obesity for incident colorectal cancer has not been clarified yet. Moreover, the effect of NAFLD and obesity for incident gastric cancer has not been clarified yet. Thus, we investigated whether NAFLD with or without obesity would be a risk factor for incident gastric cancer as well as colorectal cancer.MethodsThe study period was set from 2003 to 2016. NAFLD was diagnosed by abdominal ultrasonography using standardised criteria. We applied the Cox proportional hazards model to investigate the effect of NAFLD with or without obesity at baseline on incident gastric cancer as well as colorectal cancer. Age, sex, lifestyle factors including smoking states, alcohol consumption and exercise, and diabetes were used as covariates.ResultsDuring the study period, 27 944 individuals (16 454 men and 11 490 women) were registered in the NAfld in Gifu Area, Longitudinal Analysis study. During the mean (SD) observational period of 2357 (1458) days, incident gastric cancers were diagnosed in 48 individuals (incident rate 0.48 per 1000 person-years) and incident colorectal cancers were diagnosed in 52 individuals (incident rate 0.51 per 1000 person-years). The adjusted HR of NAFLD with obesity for incident gastric cancer was 3.58 (95% CI 1.73 to 7.38, p=0.001) and that for incident colorectal cancer was 2.96 (95% CI 1.73 to 7.38, p=0.003).ConclusionNAFLD with obesity was a risk factor for both incident gastric cancer and colorectal cancer in apparently healthy Japanese individuals.

scholarly journals Association between edible mushroom intake and the prevalence of newly diagnosed non-alcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health Cohort Study in China

2019 ◽  
Vol 123 (1) ◽  
pp. 104-112
Author(s):  
Shunming Zhang ◽  
Yeqing Gu ◽  
Min Lu ◽  
Jingzhu Fu ◽  
Qing Zhang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Antioxidant Properties ◽  
Low Grade ◽  
Inverse Association ◽  
Newly Diagnosed ◽  
Chinese Adults ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

AbstractAnimal studies have suggested that mushroom intake can alleviate non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory and antioxidant properties. However, the association between mushroom intake and NAFLD is unknown in humans. We aimed to investigate the association of mushroom intake with NAFLD among Chinese adults. This is a cross-sectional study of 24 236 adults (mean (standard deviation) age: 40·7 (sd 11·9) years; 11 394 men (47·0 %)). Mushroom intake was assessed via a validated FFQ. Newly diagnosed NAFLD was identified based on the results of annual health examinations, including ultrasound findings and a self-reported history of the disease. Multiple logistic models were used to examine the association between mushroom intake and NAFLD. The prevalence of newly diagnosed NAFLD was 19·0 %. Compared with those consuming mushrooms less frequently (≤1 time/week), the fully adjusted OR of newly diagnosed NAFLD were 0·95 (95 % CI 0·86, 1·05) for those consuming 2–3 times/week and 0·76 (95 % CI 0·63, 0·92) for those consuming ≥4 times/week (Pfor trend = 0·01). The inverse association was consistent in subgroups defined by age, sex and BMI. In conclusion, higher mushroom intake was significantly associated with lower prevalence of NAFLD among Chinese adults. Future research is required to understand the causal association between mushroom intake and NAFLD.

Sign in / Sign up

Export Citation Format

Share Document